ISSN Online: 2151-1942

Special Issue on Cancer Immunotherapy

Call for Papers

Cancer immunotherapy is a promising new cancer treatment that harnesses and enhances the innate powers of the immune system to fight cancer. The immunotherapy can be categorized as active, passive or hybrid (active and passive). It is based on the fact that cancer cells often have molecules on their surface that can be detected by the immune system.

In this special issue, we intend to invite front-line researchers and authors to submit original research and review articles on exploring **Cancer Immunotherapy**. Potential topics include, but are not limited to:

- Antibody therapy
- Cancer vaccines
- Cytokine therapy
- Cytotoxicity
- Dendritic cell therapy
- Interleukin
- Monoclonal antibodies
- Oncolytic virus therapy
- Rituximab
- T-cell therapy

Authors should read over the journal's <u>For Authors</u> carefully before submission. Prospective authors should submit an electronic copy of their complete manuscript through the journal's <u>Paper Submission System</u>.

Please kindly specify the "Special Issue" under your manuscript title. The research field "Special Issue - Cancer Immunotherapy" should be selected during your submission.

Special Issue Timetable:

Submission Deadline	December 6th, 2016
Publication Date	February 2017

Guest Editor:

For further questions or inquiries, please contact Editorial Assistant at

Journal of Cancer Therapy



ISSN Online: 2151-1942

jct@scirp.org.